All Outputs (5)

Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity (2016)
Journal Article
Bonuccelli, G., Peires-Pages, M., Ozsvari, B., Martinez- Outschoorn, U., Sotgia, F., & Lisanti, M. (2017). Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity. Oncotarget, 8(6), 9868-9884. https://doi.org/10.18632/oncotarget.14196

In this report, we systematically examined the role of telomerase activity in lung and ovarian cancer stem cell (CSC) propagation. For this purpose, we indirectly gauged telomerase activity, by linking the hTERT-promoter to eGFP. Using lung (A549)... Read More about Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity.

Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs) (2016)
Journal Article
Fiorillo, M., Lamb, R., Tanowitz, H., Cappello, A., Martinez‐Outschoorn, U., Sotgia, F., & Lisanti, M. (2016). Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs). Aging, 8(8), 1593-1607. https://doi.org/10.18632/aging.100983

Bedaquiline (a.k.a., Sirturo) is an anti‐microbial agent, which is approved by the FDA for the treatment of multi‐drug resistant pulmonary tuberculosis (TB). Bedaquiline is a first‐in‐class diaryl‐quinoline compound, that mechanistically inhibits the... Read More about Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs).

Cancer stem cell metabolism (2016)
Journal Article
Peiris-Pagès, M., Martinez-Outschoorn, U., Pestell, R., Sotgia, F., & Lisanti, M. (2016). Cancer stem cell metabolism. Breast Cancer Research, 18(55), https://doi.org/10.1186/s13058-016-0712-6

Cancer is now viewed as a stem cell disease. There is still no consensus on the metabolic characteristics of cancer stem cells, with several studies indicating that they are mainly glycolytic and others pointing instead to mitochondrial metabolism as... Read More about Cancer stem cell metabolism.

Cancer metabolism : a therapeutic perspective (2016)
Journal Article
Martinez-Outschoorn, U., Peiris-Pagés, M., Pestell, R., Sotgia, F., & Lisanti, M. (2016). Cancer metabolism : a therapeutic perspective. Nature Reviews Clinical Oncology, 14, 11-31. https://doi.org/10.1038/nrclinonc.2016.60

Awareness that the metabolic phenotype of cells within tumours is heterogeneous — and distinct from that of their normal counterparts — is growing. In general, tumour cells metabolize glucose, lactate, pyruvate, hydroxybutyrate, acetate, glutamine, a... Read More about Cancer metabolism : a therapeutic perspective.

Repurposing atovaquone : targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells (2016)
Journal Article
Fiorillo, M., Lamb, R., Tanowitz, H., Mutti, L., Krstic- Demonacos, M., Cappello, A., …Lisanti, M. (2016). Repurposing atovaquone : targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells. Oncotarget, 7(23), 34084-34099. https://doi.org/10.18632/oncotarget.9122

Atovaquone is an FDA-approved anti-malarial drug, which first became clinically available in the year 2000. Currently, its main usage is for the treatment of pneumocystis pneumonia (PCP) and/or toxoplasmosis in immune-compromised patients. Atovaquone... Read More about Repurposing atovaquone : targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells.